Company: MDCXW
Filing Date: 2025-06-23
Form Type: PRER14A
Source: 0001062993-25-012067
Chunk: 23

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-23
Form: PRER14A
Chunk 23
---
 auditing or financial reporting issue or (ii) any matter that was either the subject of (a) a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K or (b) a reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.

Policy on Audit Committee Preapproval Policies and Procedures

Consistent with SEC policies and guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and permissible non-audit services provided by our independent registered public accounting firm on a case-by-case basis. Our Audit Committee will preapprove all non-audit services to be provided to us by its external auditors. The Audit Committee may delegate to one or more of its members the authority to preapprove non audit services but preapproval by such member or members so delegated shall be presented to the full Audit Committee at its first scheduled meeting following such preapproval. All of the services relating to the fees in the table above were approved by our Audit Committee.

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "" THE APPOINTMENT AND AUTHORIZING THE BOARD TO FIX THE AUDITORS' REMUNERATION IN PROPOSAL 1.

<div align='center'>PROPOSAL 2 - ELECTION OF DIRECTORS</div>

There are currently seven directors of the Company. At the Meeting, it is proposed that eight directors are to be elected at the Meeting.

Management of the Company proposes to nominate at the Meeting each of William L. Ashton, Dr. Raza Bokhari, Robert J. Ciaruffoli, Barry Fishman, Dr. Larry Kaiser, Dr. Sara R. May, Cathy McMorris Rodgers and Ajay Raju, to serve as a director of the Company until the next Meeting at which the election of directors is considered, or until his/her successor is duly elected or appointed, unless he/she resigns, is removed, or becomes disqualified in accordance with the Articles or the OBCA. The persons named in the accompanying Proxy Card intend to vote for the election of such persons at the Meeting, unless otherwise directed. Management does not contemplate that any of the nominees will be unable to serve as a director of the Company.

<div align='center'>- 20 -</div>

The following table and the notes thereto set out the name and age of each current director and director nominee (as of the date of this proxy statement) their respective positions and, if applicable, the